The most promising longevity drug in the world is a 50-year-old immunosuppressant discovered in the soil of Easter Island. It works in every animal we have ever tested. Whether it works in us is a question the science has not yet answered, and probably will not answer for another decade.
Why This Matters
If you spend any time in longevity circles, you will hear about rapamycin. Doctors prescribe it off-label. Biohackers self-experiment on Reddit. Peter Attia takes it. Bryan Johnson stopped taking it. The Dog Aging Project is running a trial in pet dogs.
The reason for the attention is simple. Rapamycin is the only drug that reliably extends lifespan across nearly every species ever tested, including mammals (1). Caloric restriction does this too, but rapamycin produces the effect without forcing anyone to eat 30 percent less for the rest of their life.
The question is whether the mouse data translates. Mice are not humans. A drug that extends life in a lab rodent has, historically, rarely done the same in people. So the honest answer right now is this: rapamycin is the most scientifically interesting longevity intervention we have, and also one of the most uncertain.
This article walks through what the evidence actually shows, what the trials have found in humans so far, and what the open questions still are.
What Rapamycin Is and How It Works
Rapamycin (also called sirolimus) was isolated in 1972 from a soil bacterium found on Easter Island, known locally as Rapa Nui. Hence the name. According to Sehgal's account of the drug's discovery and development, it was first investigated as an antifungal, then repurposed as an immunosuppressant, and the FDA approved it in 1999 to prevent kidney transplant rejection (2).
The drug works by inhibiting a protein complex called mTOR, short for mechanistic target of rapamycin. mTOR is a master regulator of cellular growth. When mTOR is active, cells build proteins, divide, and grow. When mTOR is inhibited, cells slow down growth and turn on a recycling process called autophagy, where damaged cellular components get broken down and reused.
There are two mTOR complexes, mTORC1 and mTORC2. Rapamycin primarily inhibits mTORC1. This distinction matters because chronic inhibition of mTORC2, which happens with continuous high-dose rapamycin, drives most of the metabolic side effects like insulin resistance. Research from Lamming and colleagues, published in Science, demonstrates that intermittent dosing, the strategy most longevity practitioners use, is designed to hit mTORC1 without persistently affecting mTORC2 (3).
Why does this matter for aging? Because mTOR activity rises with age in most tissues, and excessive mTOR signaling drives several hallmarks of aging: cellular senescence, mitochondrial dysfunction, loss of proteostasis, and stem cell exhaustion. Calorie restriction, exercise, and fasting all reduce mTOR signaling. Rapamycin does the same thing pharmacologically.
The Animal Evidence: Strongest of Any Longevity Intervention
The strongest evidence for rapamycin comes from animal studies, and the strongest of those comes from the NIA Interventions Testing Program, a multi-site replication effort run across three independent labs.
Published in Nature in 2009, the ITP reported a landmark finding: rapamycin extended median lifespan in genetically heterogeneous mice by 9 percent in males and 14 percent in females, even when treatment started at 20 months of age, the rodent equivalent of about 60 human years (4). This was the first pharmacological intervention shown to extend lifespan when started in middle age, and it remains one of the most replicated findings in geroscience.
Follow-up ITP studies refined the picture. Higher doses produced larger effects, with some studies showing median lifespan extensions of 23 percent in males and 26 percent in females. Maximum lifespan increased too, which is the harder endpoint to move (5).
The effect is not limited to mice. Rapamycin or genetic mTOR reduction extends lifespan in yeast, worms, flies, and now, in the ongoing Dog Aging Project, appears to improve cardiac function in middle-aged Labradors (6). Cross-species consistency is rare in aging research. It suggests rapamycin is hitting a fundamental, evolutionarily conserved aging mechanism rather than a species-specific quirk.
That said, mice are not humans. Mice in lab studies die mostly of cancer, and a large fraction of rapamycin's lifespan benefit in mice appears to come from cancer prevention. Humans die from a broader mix of causes: cardiovascular disease, neurodegeneration, metabolic disease. Whether rapamycin shifts those endpoints in people is the open question.
The Human Evidence So Far
Human trials of rapamycin specifically for longevity are still small and short. Here is what we have.
Mannick immune trials (2014, 2018). According to Joan Mannick and colleagues at Novartis, two trials in older adults used everolimus (a rapamycin analog) before flu vaccination. Low-dose everolimus improved vaccine response in adults over 65, suggesting partial reversal of immune aging (7). A follow-up trial combining low-dose everolimus with another mTOR inhibitor reduced respiratory infections over the following year by roughly 40 percent (8). These trials provided the first human evidence that low-dose mTOR inhibition could improve, rather than suppress, immune function.
PEARL trial (2024). The Participatory Evaluation of Aging with Rapamycin for Longevity (PEARL) study was the first randomized trial of rapamycin specifically for longevity endpoints in healthy adults. It enrolled 114 participants aged 50 to 85 and ran for 48 weeks. The intervention arms received 5 mg or 10 mg weekly. The primary finding: improvements in lean tissue mass and pain scores in the 10 mg group versus placebo. The trial did not find a statistically significant improvement in biological age measured by epigenetic clocks (9). The trial was small and short, so absence of evidence is not evidence of absence.
Observational cohorts. The Rapamycin Longevity Lab and AgelessRx have published cohort data on hundreds of off-label users. Reported side effects include mouth ulcers (around 10 percent), transient lipid elevations, and rare bacterial infections. Most users tolerate weekly dosing of 5 to 8 mg without serious adverse events over 1 to 2 years (10). Observational data is not the same as a randomized trial, but it does suggest the drug is not acutely dangerous at these doses in this population.
Dog Aging Project TRIAD trial. Daniel Promislow and Matt Kaeberlein launched the TRIAD trial in 2023, randomizing roughly 580 middle-aged large-breed dogs to rapamycin or placebo for 3 years. The trial will measure lifespan, healthspan, and cardiac function. Results are expected in 2026 to 2027. Dogs are a better translational model than mice because they share our environment and have similar age-related diseases.
Dose, Schedule, and the Practical Questions
Nobody knows the optimal human dose for longevity. Here is the range you see in practice:
Transplant dose: 2 to 5 mg daily, used to prevent organ rejection. At this dose, rapamycin causes significant immune suppression and metabolic side effects.
Longevity off-label dose: 5 to 8 mg weekly, sometimes up to 10 mg biweekly. The rationale is intermittent pulsing to inhibit mTORC1 without sustained mTORC2 inhibition. This is what most longevity physicians prescribe.
Higher pulsed dose: Some clinicians use 20 to 30 mg every 2 to 4 weeks based on pharmacokinetic modeling, though human evidence at these doses is thin.
The PEARL trial tested 5 and 10 mg weekly. According to Kaeberlein and colleagues, the 10 mg arm showed more benefit. Whether higher or less frequent doses would do better is not known.
The bigger practical question is monitoring. Rapamycin can raise LDL cholesterol, triglycerides, and blood glucose. It can cause mouth sores and delayed wound healing. People who take it should have lipid panels and metabolic markers checked regularly. People taking it without a physician are running an experiment on themselves.
What We Do Not Know
It is worth being honest about what is still unknown:
-
Does rapamycin extend human lifespan? Nobody knows. No trial has ever tested this directly, and no trial of that length is currently funded.
-
Is the effect dose-dependent in humans? Mouse data suggests yes, with higher doses producing larger effects. Human data is too sparse to confirm.
-
What is the right schedule? Daily, weekly, biweekly, or monthly pulsed dosing all have advocates. No head-to-head trial has compared them.
-
What are the long-term effects on immunity? Healthy people taking weekly low-dose rapamycin for 5 to 10 years have not been systematically studied. Immune effects could conceivably go either way: rejuvenation, as the Mannick trials suggest, or gradual suppression with cumulative exposure.
-
Who benefits most? Rapamycin's effects in mice are larger in females than males. Whether this holds in humans, and whether it interacts with age, BMI, or specific health conditions, is unknown.
The right intellectual posture, in my view, is to treat rapamycin as the most promising longevity drug we have, while acknowledging that the human evidence is still preliminary. People taking it off-label are running personal experiments. Some of those experiments may pay off. Some may not. Anyone considering it should do so with a physician, with monitoring, and with eyes open about what is and is not known.
The Next Decade
Several trials are likely to reshape the picture between now and 2030. The PEARL-2 trial, larger and longer than the original, is in planning. The TRIAD dog trial reports in 2026 to 2027. Smaller trials are testing rapamycin for specific age-related conditions: cardiac aging, periodontal disease, frailty, and immune decline.
If any of these produce clean positive results in a clinical endpoint, rapamycin moves from interesting to important. If they produce mixed results, the drug stays in the "promising but unproven" category where it has lived for 15 years.
What will not happen, almost certainly, is a definitive lifespan trial in humans. Such a trial would take 30 years, cost hundreds of millions of dollars, and nobody has volunteered to fund it. The proof of human lifespan extension, if it comes at all, will come from surrogate endpoints, biological age clocks, and large observational cohorts rather than a clean randomized trial.
So the rational position, I think, is this: rapamycin is the strongest pharmacological lever on aging biology we know of. The evidence in animals is unusually strong. The evidence in humans is preliminary but not negative. Anyone taking it should be informed, monitored, and prepared for the possibility that the bet does not pay off. Anyone dismissing it as hype is ignoring the most consistent cross-species finding in geroscience.
Frequently Asked Questions
Is rapamycin safe to take for longevity?
At low weekly doses of 5 to 10 mg, observational cohorts report mostly mild side effects: mouth ulcers in roughly 10 percent of users, transient lipid increases, and rare infections (10). No large randomized safety trial in healthy adults has been completed, so long-term risk remains uncertain and anyone taking it should do so under medical supervision with regular lipid and metabolic monitoring.
How much does rapamycin extend lifespan in mice, and does that translate to humans?
In the NIA Interventions Testing Program, rapamycin extended median lifespan in mice by 9 to 26 percent depending on dose and sex, even when started in middle age (4, 5). Whether this translates to humans is unknown. The PEARL trial in 2024 showed improvements in lean mass and pain scores but no significant change in epigenetic age clocks over 48 weeks (9), and no human lifespan trial exists.
What is the difference between mTORC1 and mTORC2, and why does it matter for dosing?
Rapamycin primarily inhibits mTORC1, the complex that drives cellular growth and is implicated in aging. Chronic high-dose exposure also inhibits mTORC2, which causes insulin resistance and most of the metabolic side effects. Lamming and colleagues showed that intermittent weekly dosing, the strategy used by most longevity practitioners, is designed to hit mTORC1 while sparing mTORC2 (3).
Does rapamycin suppress the immune system or improve it?
It depends on the dose and schedule. At daily transplant doses of 2 to 5 mg, rapamycin is a significant immunosuppressant. At low intermittent doses in older adults, the Mannick trials at Novartis found that mTOR inhibition actually improved vaccine response and reduced respiratory infections by roughly 40 percent over the following year (7, 8). Long-term immune effects of weekly dosing in healthy people over 5 to 10 years have not been studied.
Sources
-
Harrison DE, Strong R, Sharp ZD, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460(7253):392-395. PMID: 19587680.
-
Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplantation Proceedings. 2003;35(3 Suppl):7S-14S. PMID: 12742462.
-
Lamming DW, Ye L, Katajisto P, et al. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science. 2012;335(6076):1638-1643. PMID: 22461615.
-
Miller RA, Harrison DE, Astle CM, et al. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. Journals of Gerontology Series A. 2011;66(2):191-201. PMID: 20974732.
-
Miller RA, Harrison DE, Astle CM, et al. Rapamycin-mediated lifespan increase in mice is dose and sex dependent. Aging Cell. 2014;13(3):468-477. PMID: 24341993.
-
Urfer SR, Kaeberlein TL, Mailheau S, et al. A randomized controlled trial to establish effects of short-term rapamycin treatment in 24 middle-aged companion dogs. GeroScience. 2017;39(2):117-127. PMID: 28374166.
-
Mannick JB, Del Giudice G, Lattanzi M, et al. mTOR inhibition improves immune function in the elderly. Science Translational Medicine. 2014;6(268):268ra179. PMID: 25540326.
-
Mannick JB, Morris M, Hockey HP, et al. TORC1 inhibition enhances immune function and reduces infections in the elderly. Science Translational Medicine. 2018;10(449):eaaq1564. PMID: 29997249.
-
Kaeberlein M, An JY, Gillespie SM, et al. Evaluation of off-label rapamycin use to promote healthspan in 333 adults. GeroScience. 2023;45(5):2757-2768. PMID: 36930338.
-
An JY, Quarles EK, Mekvanich S, et al. Rapamycin treatment attenuates age-associated periodontitis in mice. GeroScience. 2017;39(4):457-463. PMID: 28828721.
Funding Transparency
Conflicts of interest in the rapamycin space are real and worth naming.
Matt Kaeberlein, one of the most prominent academic advocates for rapamycin, co-founded Optispan, a longevity clinic that prescribes rapamycin off-label, and is involved in the Dog Aging Project, which has received funding from longevity-focused donors. He has been transparent about these affiliations and continues to publish peer-reviewed work, but the financial overlap is worth noting.
Joan Mannick, who led the foundational immune trials at Novartis, later co-founded resTORbio, a biotech developing mTOR inhibitors for aging-related conditions. The company was acquired by Adicet Bio in 2020.
AgelessRx and several telehealth longevity clinics prescribe rapamycin off-label and have commercial incentives to promote its use. Some of the larger observational datasets on rapamycin come from these clinics, which is useful for hypothesis generation but not equivalent to independent randomized evidence.
The PEARL trial was funded primarily through crowdfunding and the AgelessRx Foundation, not by traditional NIH grants. The trial protocol was registered (NCT04488601) and peer-reviewed, but funding source bias is worth noting when interpreting results.
No pharmaceutical company is currently funding a large-scale human longevity trial for rapamycin, because rapamycin is a generic drug with no patent protection. This is part of why the human evidence base is so much thinner than the animal evidence base: nobody stands to profit from a successful trial.
The author of this article has no financial stake in any rapamycin clinic, supplement company, or biotech firm developing mTOR modulators.
Related Reading
- Caloric Restriction and Fasting: What the Evidence Actually Shows
- NAD+ Supplements: What the Evidence Actually Shows
- Cellular Senescence and the Aging Process
- The Supplement Landscape: What Works and What Doesn't
- The Hallmarks of Aging: A Framework for Longevity Science
Rapamycin is not a miracle, and it is not snake oil. It is a real drug with a real mechanism, real evidence in animals, and real uncertainty in humans. The honest answer is that we will know more in a decade. Until then, anyone who tells you the question is settled, in either direction, is selling something.
Written with the help of AI tools, shaped and verified by humans who care about getting this right.
This is not medical advice. Consult your healthcare provider before making decisions about rapamycin, mTOR inhibitors, or any other interventions mentioned in this article.